SCHEMBL2081972

SCHEMBL2081972

Cc1ccn(-c2ncnc3c(C(=O)C(=O)N4CCN(C(=O)c5ccccc5)CC4)c[nH]c23)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 6/20 0.54
CYP2C9 P11712 5/20 0.54
CYP2D6 P10635 5/20 0.54
CYP3A4 P08684 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C8 P10632 1/20 0.54
CYP2B6 P20813 1/20 0.54
KCNH2 Q12809 1/20 0.54
MGLL Q99685 1/20 0.43
KIT P10721 1/20 0.42
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 1/20 0.39
P2RY12 Q9H244 2/20 0.39
MEN1 O00255 1/20 0.39
BTK Q06187 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2080357 0.89 CYP3A4 (0.51) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2078389 0.88 CYP3A4 (0.50) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2080459 0.88 CYP3A4 (0.50) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2078406 0.87 CYP2C19 (0.70) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2080469 0.87 CYP3A4 (0.49) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2080762 0.86 CYP3A4 (0.49) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2080255 0.86 CYP3A4 (0.55) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2078680 0.85 CYP3A4 (0.52) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2079828 0.84 CYP3A4 (0.56) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2
SCHEMBL2079747 0.84 CYP3A4 (0.47) CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902204-B2 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 US disclosed
US-7902204-B2 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 US disclosed
US-7902204-B2 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 US disclosed
EP-1751161-B1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2010-07-14 EP disclosed
EP-1751161-B1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2010-07-14 EP disclosed
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-05-29 US disclosed
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-05-29 US disclosed
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-05-29 US disclosed
US-20050124623-A1 For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS SILEO, LLC 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS ZC3HAV1, ZC3HAV1L, EIF2AK2 CYP2C19 1501/4885CYP2C9 1769/4885CYP2D6 643/4885
US-20050124623-A1 For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS CD4, CCR5, PAICS CYP2C19 896/4885CYP2C9 1869/4885CYP2D6 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.